(Q34606231)

3 August 2017

title

The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa (English)

1 reference

3 August 2017

0 references

0 references

1 reference

Richard Kaplan

3

0 references

Sean Emery

object named as

Sean Emery

6

0 references

Mark A Boyd

object named as

Mark A Boyd

8

0 references

author name string

Karen Schneider

1

1 reference

3 August 2017

Chidi Nwizu

2

1 reference

3 August 2017

Jonathan Anderson

4

1 reference

3 August 2017

David P Wilson

5

1 reference

3 August 2017

David A Cooper

7

1 reference

3 August 2017

language of work or name

English

0 references

publication date

15 February 2013

1 reference

3 August 2017

1 reference

3 August 2017

volume

8

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

e54435

1 reference

Creative Commons Attribution 4.0 International

3 August 2017

copyright license

start time

15 February 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574122

Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574122

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574122

Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574122

Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574122

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574122

Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574122

Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574122

Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574122

The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa--a primary data analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574122

The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574122

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574122

The will to live among HIV-infected patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574122

The cost-effectiveness of preventing AIDS-related opportunistic infections

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574122

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574122

Counseling and testing for HIV prevention: costs, effects, and cost-effectiveness of more rapid screening tests.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574122

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

7 July 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0054435

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0054435

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0054435

A meta-analysis of utility estimates for HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0054435

Utilities Derived from Visual Analog Scale Scores in Patients with HIV/AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0054435

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0054435

Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574122

Comparison of Health State Utilities Using Community and Patient Preference Weights Derived from a Survey of Patients with HIV/AIDS

26 October 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0054435

What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23457450

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Cost comparison of three HIV counseling and testing technologies

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23457450

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Probabilistic analysis of decision trees using Monte Carlo simulation

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23457450

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1371/JOURNAL.PONE.0054435

1 reference

3 August 2017

0 references

1 reference

3 August 2017

1 reference